Showing 5041-5050 of 8475 results for "".
- Can Phages Help Treat AD?https://practicaldermatology.com/news/can-phages-help-treat-adp/2462033/Bacteriophages or bacteria eaters may be a new therapy option for people with atopic dermatitis (AD), according to a study in Science Advances. A MedUni Vienna team has investigated t
- FDA Approves Merz Aesthetics’ Belotero Balance (+) for Infraorbital Hollowshttps://practicaldermatology.com/news/fda-approves-merz-aesthetics-belotero-balance-for-infraorbital-hollows/2462028/The U.S. Food and Drug Administration (FDA) approved Merz Aesthetics’ Belotero Balance (+) for improvement of the infraorbital hollow (IOH) in adults over the age of 21. This approval stems from positive pivotal study results demonstrating the efficacy and safety o
- Arcutis Launches Educational Campaign for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-educational-campaign-for-people-living-with-seborrheic-dermatitis/2462021/Arcutis Biotherapeutics, Inc. is launching
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- Almirall Launches New Campaign, Atopic Museum for World Eczema Dayhttps://practicaldermatology.com/news/almirall-launches-new-campaign-atopic-museum-for-world-eczema-day/2462003/Almirall unveiled its atopic dermatitis awareness campaign "Moving aheAD" for World Atopic Eczema Day. The campaign includes the “Atopic M
- Hillstream Enters Into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritishttps://practicaldermatology.com/news/hillstream-enters-into-an-exclusive-option-agreement-to-acquire-a-clinical-stage-asset-for-chronic-pruritis/2461994/Hillstream BioPharma, Inc. is set to acquire AV104 for chronic pruritis. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis. The Company intends to first seek approval in an orphan disease for the treatment of mode
- Houston Dermatologist Rolls Out New Class of Topical Pain Relievershttps://practicaldermatology.com/news/houston-dermatologist-rolls-out-new-class-of-topical-pain-relievers/2461974/Milton D. Moore, MD, a dermatologist and founder & CEO of Moore Unique Skin Care, LLC and
- Kenvue Launches Two New Tylenol Precise Pain-relieving Creamshttps://practicaldermatology.com/news/kenvue-launches-two-new-tylenol-precise-pain-relieving-creams/2461973/Kenvue Inc. is rolling out two new topical pain-relieving creams: Tylenol Precise Pain Relieving Cream and Tylenol Precise Cooling Pain Relieving Cream. These are among the first U.S. product launches from Kenvue since it became a publicly traded
- Study Links Gut Microbiome and Eczema in Infancyhttps://practicaldermatology.com/news/study-links-gut-microbiome-and-eczema-in-infancy/2461971/New research has revealed associations between the gut microbiome and eczema in infancy and has established the basis for the potential prevention and treatment of eczema via modulation of the gut microbiota. The study was
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval cove